“King heirs hold first business meeting since 2004 - Charleston Daily Mail” plus 4 more |
- King heirs hold first business meeting since 2004 - Charleston Daily Mail
- Xerox buying Affiliated Computer Services as printer company beefs up ... - Hartford Courant
- Abbott buys Solvay pharma operations for $6.6B - Salon
- Xerox, Abbott deals boost stocks; Dow gains 135 - Island Packet Online
- Xerox, Abbott deals boost stocks; Dow gains 140 - Tacoma News Tribune
| King heirs hold first business meeting since 2004 - Charleston Daily Mail Posted: 28 Sep 2009 09:01 AM PDT ATLANTA (AP) - The surviving children of the Rev. Martin Luther King Jr. have met to formally discuss estate business for the first time in five years. Martin Luther King III, the Rev. Bernice King and Dexter King are the remaining heirs of their father's estate, which is a privately held corporation. The siblings are in the midst of a legal feud, with Martin King and Bernice King claiming Dexter King has acted improperly as head of the estate. Fulton County Superior Court spokesman Don Plummer says all three appeared in a courtroom Monday for a closed-door shareholders meeting that had been ordered by a judge. The Kings last held an annual meeting to discuss the estate in 2004. Dexter King has also sued his sister over her handling of their mother's estate, which Bernice King runs. |
| Xerox buying Affiliated Computer Services as printer company beefs up ... - Hartford Courant Posted: 28 Sep 2009 06:10 AM PDT NEW YORK (AP) — Xerox Corp. said Monday it will buy Affiliated Computer Services Inc. for $6.4 billion in cash and stock, joining the expensive race among technology companies to broaden their offerings. Xerox said the deal will create a $22 billion business that combines Xerox's copiers, printers and document management services with the "business process outsourcing" of Dallas-based ACS. Outsourcers like ACS take on tasks for other companies, such as helping to manage payroll or run health care plans. Xerox's offer amounted to a 33 percent premium over ACS's closing stock price on Friday, although the value fell as Xerox shares lost $1.47, or 16 percent, to $7.50 in morning trading, while ACS shares jumped $6.53, or 14 percent, to $53.78. The move takes Xerox deeper into the back-office operations of its business customers with the kind of acquisition that is popping up more and more as technology companies add a greater variety of equipment and services under a single tent. Last week Dell Inc. said it would buy Perot Systems Corp. for $3.9 billion, kick-starting an information-technology services business for the company. That comes a year after rival Hewlett-Packard Co. expanded its own services business with the $13.9 billion buyout of Electronic Data Systems Corp. Business software maker Oracle Corp. also hopes to become more of a one-stop shop by closing a $7.4 billion deal for computer server and software maker Sun Microsystems Inc. ACS, a $6.5 billion company with about 74,000 employees and profit of $350 million in its last fiscal year, offers a range of services, such as helping companies manage health care plans and accounting. It has customers in government, transportation, health care and retail. By buying ACS, Xerox sees a way to boost profits and expand the roles it can play in assisting clients with running their businesses. "They've told us they need a little bit more help," Xerox CEO Ursula Burns said in an interview, adding, "This is not just two companies coming together to get costs down." ACS's chief executive, Lynn Blodgett, offered automated toll collection as an example. For E-Z Pass, the electronic toll system in the Northwest, ACS gathers images of cars passing through tollbooths and has employees record license plate numbers manually for processing payments. Xerox has image-recognition technology that could automate that process and might take it a step further, checking to see if a car is up to date on its registration. The deal marks Burns's first big move since she took charge of Xerox on July 1. Although still profitable, Xerox has been hurt by the slowdown in spending by businesses during the recession. Apart from selling printers and copiers, Xerox gets most of its revenue from leasing equipment and charging for supplies and helping companies manage their documents. Xerox said buying ACS will triple its services revenue to an estimated $10 billion next year. In a conference call with analysts, Xerox Chief Financial Officer Larry Zimmerman said only about 20 percent of ACS and Xerox customers overlap, meaning the companies will have an opportunity to sell those clients more products. In particular, Xerox hopes to expand the overseas reach of ACS, which does more than 90 percent of its business in the U.S. ACS stockholders will receive $18.60 per share in cash plus 4.935 Xerox shares for each ACS share they own. Xerox, based in Norwalk, Conn., will also take on $2 billion of ACS's debt and issue $300 million of convertible preferred stock to ACS's Class B shareholders. The acquisition, which was approved by both companies' boards, is expected to add to adjusted earnings results in the first year. Xerox expects to save $300 million to $400 million in the first three years after the deal closes, which is targeted for the first quarter of 2010. The companies said ACS will function independently and will be headed by Blodgett, who will report to Burns. ___ AP Business Writer Michelle Chapman contributed to this report. Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. |
| Abbott buys Solvay pharma operations for $6.6B - Salon Posted: 28 Sep 2009 05:55 AM PDT Sep 28th, 2009 | NEW YORK -- Abbott Laboratories on Monday said it would pay $6.6 billion for the pharmaceutical business of Belgian chemicals maker Solvay in a move to further expand internationally and add to its product portfolio. The deal is the latest in a string of drug mergers and acquisitions, and one of three announcements Monday that involved the fast-growing vaccines business. By purchasing Brussels-based Solvay, Abbott gains access to emerging markets in Eastern Europe and Asia along with new therapeutic areas, including hormone therapies and vaccines. Solvay's flu vaccine Influvac will give Abbott an entrant in the burgeoning vaccines market, which is currently dominated by European pharmaceutical giants like GlaxoSmithKline and Novartis. Also on Monday, Johnson & Johnson bought an 18 percent stake in Dutch biotechnology company Crucell NV, which is trying to develop a universal flu vaccine, while competitor Merck acquired the rights to sell Australia-based CSL Ltd.'s Afluria flu vaccine in the U.S. North Chicago, Ill.-based Abbott already holds U.S. marketing rights for Solvay's Trilipix and TriCor, drugs which raise "good" HDL cholesterol while reducing triglycerides and "bad" LDL cholesterol. Solvay's other top-selling drugs include the Parkinson's disease treatment Duodopa and hormone therapy drugs AndroGel and Duphaston. Monday's announcement is the latest in a string of mergers and acquisitions, as cash-rich pharmaceutical companies race to acquire new products amid looming patent expirations. Earlier this year Swiss drugmaker Roche acquired biotech pioneer Genentech following similar deals uniting Pfizer Inc. and Wyeth, and Merck & Co. Inc. with Schering-Plough. Analysts said Abbott's purchase was designed to diversify Abbott's revenue stream, more than 35 percent of which relies on the blockbuster drug Humira. The injectable drug, which will lose patent protection in 2016, treats rheumatoid arthritis and other inflammatory diseases. Wall Street appeared to back the deal, sending Abbott shares up $1.57, or 3.3 percent, in midday trading. But Credit Suisse analyst Catherine Arnold had doubts about how much new revenue the deal would generate, especially considering the patent on Tricor expires in two years. "Solvay does not add long-term growth or reduce Abbott's dependence of growth on Humira," Arnold wrote in a research note. Morgan Stanley's David Lewis said the deal offers "marginal diversification," but would give Abbott greater access to markets in Europe and elsewhere. More than 25 percent of Solvay's $3 billion in revenue last year came from emerging markets, including Russia, India and Brazil. Miles D. White, chairman and chief executive of Abbott, said the deal could add up to $3 billion in additional annual sales, while giving the company more diverse portfolios in cardiology and neuroscience treatment areas. It also gives the company $500 million in additional research and development capacity, that can be used to drive future pharmaceutical unit growth, White said. "We are adding from a position of strength," White said, citing the company's sales in international and emerging markets. Solvay said in a statement the sale will let it "refocus" its activities, which also cover chemicals and plastics. "We are building a new refocused group with the financial means to further accelerate sustainable growth," Alois Michielsen, Solvay's chairman, said. Solvay said the deal's value could jump by another $439 million if sales targets are met for certain drug products. In addition, Abbott would also take on liabilities worth about $584 million. The sale is expected to close in the first quarter of 2010, pending antitrust approval from the EU and U.S. Abbott makes and markets pharmaceutical and medical products in more than 130 countries and employs more than 72,000 people. In the last year, it has bought contact lens maker Advanced Medical Optics, India-based Wockhart's nutritional business, eye care company Visiogen and Evalve, a maker of heart repair equipment. Growth of the company's pharmaceutical unit has been driven by Humira, which had sales of $4.5 billion last year. Solvay Pharmaceuticals is a group of companies that employs 9,000 people worldwide and had sales of 2.7 billion euros in 2008. The Solvay Group as a whole employs more than 29,000 people in 50 countries. Its 2008 consolidated sales were 9.5 billion euros. (This version CORRECTS the name of a company that Abbott bought to Visiogen.) |
| Xerox, Abbott deals boost stocks; Dow gains 135 - Island Packet Online Posted: 28 Sep 2009 08:54 AM PDT NEW YORK — Corporate dealmaking is boosting investors' hopes for a recovery in the economy. Stocks jumped Monday after Abbott Laboratories said it would buy the pharmaceutical business of Belgian chemicals maker Solvay for $6.6 billion and Xerox Corp. agreed to acquire Affiliated Computer Services for about $6.4 billion. A weaker dollar is boosting commodity prices, which in turn helped send materials and energy stocks higher. All major indexes rose more than 1 percent, including the Dow Jones industrial average, which added 140 points. The takeover moves are a welcome sign that businesses have enough faith in a recovery in the economy to pursue acquisitions. In the past year, companies grew so worried about the economy that they were hesitant to part with cash and often had trouble lining up financing. "It's encouraging to all investors when you see companies buy because basically what that says is they're in a more aggressive mode as opposed to being in the fetal position," said Mark Coffelt, portfolio manager at Empiric Funds in Austin, Texas. In midday trading, the Dow rose 140.12, or 1.5 percent, to 9,805.31. The broader Standard & Poor's 500 index rose 18.75, or 1.8 percent, to 1,063.13, and the Nasdaq composite index rose 46.30, or 2.2 percent, to 2,137.22. The market's rise follows its worst week since early July. Bond prices were mixed. The yield on the benchmark 10-year Treasury note, which moves opposite its price, rose to 3.33 percent from 3.32 percent late Friday. The dollar mostly fell against other currencies, while gold prices rose. Abbott Labs rose $1.66, or 3.5 percent, to $48.99. Affiliated Computer jumped $5.94, or 12.6 percent, to $53.19, while Xerox fell $1.58, or 17.6 percent, to $7.39. Johnson & Johnson Inc. bought an 18 percent stake in Dutch biotechnology company Crucell NV for $440 million in hopes of developing a universal flu vaccine, the companies said. J&J rose 76 cents, or 1.3 percent, to $61.38. Crude rose $1.14 to $67.16 a barrel on the New York Mercantile Exchange as the dollar slid. Commodities are priced in dollars so a weak greenback makes them more appealing to foreign buyers. More than four stocks rose for every one that fell on the New York Stock Exchange, where volume came to 343.6 million shares compared with 431.6 million shares traded at the same point Friday. Trading was light as some market participants were out for Yom Kippur, the holiest day of the Jewish calendar. The Russell 2000 index of smaller companies rose 14.21, or 2.4 percent, to 613.15. Overseas, Japan's Nikkei stock average fell 2.5 percent. In afternoon trading, Britain's FTSE 100 rose 1.4 percent, Germany's DAX index rose 2.3 percent, and France's CAC-40 advanced 1.8 percent. |
| Xerox, Abbott deals boost stocks; Dow gains 140 - Tacoma News Tribune Posted: 28 Sep 2009 08:47 AM PDT Corporate dealmaking is boosting investors' hopes for a recovery in the economy. Stocks jumped Monday after Abbott Laboratories said it would buy the pharmaceutical business of Belgian chemicals maker Solvay for $6.6 billion and Xerox Corp. agreed to acquire Affiliated Computer Services for about $6.4 billion. A weaker dollar is boosting commodity prices, which in turn helped send materials and energy stocks higher. All major indexes rose more than 1 percent, including the Dow Jones industrial average, which added 140 points. The takeover moves are a welcome sign that businesses have enough faith in a recovery in the economy to pursue acquisitions. In the past year, companies grew so worried about the economy that they were hesitant to part with cash and often had trouble lining up financing. "It's encouraging to all investors when you see companies buy because basically what that says is they're in a more aggressive mode as opposed to being in the fetal position," said Mark Coffelt, portfolio manager at Empiric Funds in Austin, Texas. In midday trading, the Dow rose 140.12, or 1.5 percent, to 9,805.31. The broader Standard & Poor's 500 index rose 18.75, or 1.8 percent, to 1,063.13, and the Nasdaq composite index rose 46.30, or 2.2 percent, to 2,137.22. The market's rise follows its worst week since early July. Bond prices were mixed. The yield on the benchmark 10-year Treasury note, which moves opposite its price, rose to 3.33 percent from 3.32 percent late Friday. The dollar mostly fell against other currencies, while gold prices rose. Abbott Labs rose $1.66, or 3.5 percent, to $48.99. Affiliated Computer jumped $5.94, or 12.6 percent, to $53.19, while Xerox fell $1.58, or 17.6 percent, to $7.39. Johnson & Johnson Inc. bought an 18 percent stake in Dutch biotechnology company Crucell NV for $440 million in hopes of developing a universal flu vaccine, the companies said. J&J rose 76 cents, or 1.3 percent, to $61.38. Crude rose $1.14 to $67.16 a barrel on the New York Mercantile Exchange as the dollar slid. Commodities are priced in dollars so a weak greenback makes them more appealing to foreign buyers. More than four stocks rose for every one that fell on the New York Stock Exchange, where volume came to 343.6 million shares compared with 431.6 million shares traded at the same point Friday. Trading was light as some market participants were out for Yom Kippur, the holiest day of the Jewish calendar. The Russell 2000 index of smaller companies rose 14.21, or 2.4 percent, to 613.15. Overseas, Japan's Nikkei stock average fell 2.5 percent. In afternoon trading, Britain's FTSE 100 rose 1.4 percent, Germany's DAX index rose 2.3 percent, and France's CAC-40 advanced 1.8 percent. |
| You are subscribed to email updates from Business - Bing News To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
